Can you take metformin with Ozempic, Mounjaro or another GLP-1?
Reviewed 14 sourcesPublished by PepVault
Yes: Ozempic and Mounjaro were tested on top of metformin, and no label lists it as an interaction. What the five labels flag, side by side, and when to call.

- Last reviewed
- Sources
- 14
- Questions
- 7
- Compounds
- 4
The short answer
Yes. Metformin is the drug a GLP-1 is most often added to: Ozempic and Mounjaro were tested largely on top of it, and none of the Ozempic, Wegovy, Mounjaro or Zepbound labels lists metformin as an interaction. The overlap to watch is the gut. Both can cause nausea or diarrhea, and losing fluids strains the kidneys that clear metformin. Your prescriber sets both doses.
Evidence: FDA labels for Ozempic, Wegovy, Mounjaro, Zepbound, the semaglutide tablets and metformin, and large randomized phase 3 trials that ran a GLP-1 on top of metformin; on adding metformin to a GLP-1 for weight, only two small randomized trials in women with PCOS.

What do the labels say about taking metformin with a GLP-1?
Each label has a drug interactions section, section 7. Read side by side, the four GLP-1 labels name the same two things: insulin or a sulfonylurea (an older pill such as glipizide that pushes insulin out whatever your blood sugar is), because together they can drop blood sugar too low, and pills in general, because a GLP-1 slows how fast the stomach empties1234. Metformin is not named as a problem in any of them. Metformin's own label does not name GLP-1 drugs either5.
| Label | What its interactions section names | Metformin |
|---|---|---|
| Ozempic (semaglutide)1 | Insulin or a sulfonylurea (low blood sugar); pills, since the stomach empties more slowly | Tested with semaglutide 1 mg: no clinically relevant change |
| Wegovy (semaglutide)2 | The same two, plus closer checks on pills with a narrow safe range; the semaglutide tablet raised levothyroxine exposure 33% | Listed among drugs with no clinically significant change |
| Mounjaro (tirzepatide)3 | Insulin or a sulfonylurea; pills with a narrow safe range such as warfarin; birth-control pills need a backup method for 4 weeks after the start and after each dose step | Not named; its diabetes trials ran on top of metformin |
| Zepbound (tirzepatide)4 | The same as Mounjaro | Not named |
| Metformin5 | Insulin or a sulfonylurea (low blood sugar); ranolazine, vandetanib, dolutegravir and cimetidine (they raise metformin levels); topiramate and similar drugs; heavy drinking | GLP-1 drugs are not named |
PepVault holds a weekly shot and a twice-daily tablet in one protocol, each with its own reminder, so the metformin doses and the shot day sit on the same Today screen. Set reminders in PepVault
One line in the labels does rule out a pairing, and it is not metformin. Wegovy and Zepbound both say that using them with any other GLP-1 medicine, or another product with the same drug in it, is not recommended24. So Ozempic with Mounjaro is the combination to avoid; metformin with either is the ordinary one.

Did any study combine metformin and a GLP-1?
Most of the big diabetes trials did. Metformin is the usual first drug for type 2 diabetes, so the phase 3 programs for semaglutide (SUSTAIN for the shot, PIONEER for the pill) and tirzepatide (SURPASS) mostly added the new drug to it. HbA1c is the blood test that reads your average blood sugar over about three months.
| Trial | People and background | HbA1c change | Weight change |
|---|---|---|---|
| SURPASS-2, 40 weeks37 | 1,879 adults with type 2 diabetes, all on metformin alone; tirzepatide 5, 10 or 15 mg vs semaglutide 1 mg | -2.0, -2.2, -2.3 points vs -1.9 | -7.6, -9.3, -11.2 kg vs -5.7 kg |
| SUSTAIN 2, 56 weeks18 | 1,231 adults on metformin, a thiazolidinedione or both; Ozempic 0.5 or 1 mg vs sitagliptin | -1.3, -1.5 points vs -0.7 | -4.2, -5.5 kg vs -1.7 kg |
| Ozempic 2 mg trial, 40 weeks1 | 961 adults on metformin, with or without a sulfonylurea; Ozempic 2 mg vs 1 mg | -2.1 points vs -1.9 | -6.4 kg vs -5.6 kg |
| PIONEER 2, 52 weeks9 | 822 adults on metformin; semaglutide pill 14 mg vs empagliflozin 25 mg | -1.3 points vs -0.9 at 26 weeks | -4.7 kg vs -3.8 kg at 52 weeks |
| STEP 2, 68 weeks210 | 1,210 adults with type 2 diabetes, on diet alone or 1 to 3 diabetes pills including metformin; Wegovy 2.4 mg vs placebo | Not the main endpoint | -9.6% vs -3.4% of body weight |
| SURMOUNT-2, 72 weeks411 | 938 adults with type 2 diabetes, on diet alone or any diabetes pill except a DPP-4 inhibitor; tirzepatide 10 or 15 mg vs placebo | Not the main endpoint | -12.8%, -14.7% vs -3.2% of body weight |
A pooled look at SUSTAIN 2, 3, 4 and 10 split 3,411 people by what they already took: metformin alone, or metformin with a sulfonylurea. Semaglutide lowered HbA1c and weight more than the comparison drug on either background, and stopping for side effects ran about the same on both12.
What no large trial has tested is the reverse question: does adding metformin to semaglutide or tirzepatide take off more weight than the GLP-1 alone? We found none. The closest are small trials in women with polycystic ovary syndrome (PCOS). In 44 women, liraglutide 1.2 mg (an older daily GLP-1) plus metformin took off 6.2 kg in 12 weeks, against 3.8 kg on liraglutide alone13. The newer PCOS trials ran it the other way round: in 100 women, semaglutide plus metformin took off 6.1 kg in 16 weeks against 2.3 kg on metformin alone; with no semaglutide-only group, it shows what the GLP-1 added14. Our GLP-1s and PCOS guide covers those trials in full.
Does a GLP-1 change how metformin works?
Not in a way the studies could measure for semaglutide. A GLP-1 slows the stomach, which in theory could change how fast a pill is absorbed, so it was tested: with semaglutide 1 mg at steady state, metformin's blood levels showed no clinically relevant change, and the Ozempic label says no dose adjustment is needed1. The semaglutide tablet studies found the same for metformin6. The tirzepatide labels list no metformin study; their measured slowing was largest after the first 5 mg dose, which cut the peak level of a test pill (acetaminophen) by half and delayed it an hour, and had faded by week 43.
The two drugs lower blood sugar in different ways, which is why they stack. Metformin makes the liver release less sugar into the blood and helps the body respond to its own insulin5. A GLP-1 tells the pancreas to release insulin only while blood sugar is high, slows the stomach and quiets appetite1. Neither forces insulin out when sugar is already normal.
Will metformin and a GLP-1 together drop your blood sugar too low?
Rarely, as long as neither is paired with insulin or a sulfonylurea. In SURPASS-2, where everyone was on metformin and nothing else, a reading under 54 mg/dL came in 0.2% to 1.7% of people on tirzepatide and 0.4% on semaglutide over 40 weeks7. In Zepbound's diabetes trial, lows under 54 mg/dL hit 2.1% of people on Zepbound without a sulfonylurea and 10.3% with one4. Metformin's label names the same pairing: combined with insulin or a sulfonylurea it can raise the risk of lows, and those may need a lower dose5.
If you also take insulin or a sulfonylurea, the four GLP-1 labels ask the prescriber to consider lowering that dose when the GLP-1 starts, and metformin's label says it may need lowering too12345.
Are the stomach side effects worse on both?
No trial measured the extra, because nearly everyone in the GLP-1 diabetes trials was already on metformin: the GLP-1 rates below are already the combined rates. Both drugs land in the gut first, so the effects overlap. In metformin's label trial, diarrhea came in 53% of people against 12% on placebo, and nausea or vomiting in 26% against 8%5. On top of metformin in SURPASS-2, nausea came in 17% to 22% of people on tirzepatide and 18% on semaglutide, diarrhea in 13% to 16% and 12%, vomiting in 6% to 10% and 8%, mostly mild to moderate7. Both labels start low and step up for exactly this reason: metformin by 500 mg a week, with meals5, and the GLP-1s over 4-week steps13.
Commonly reported: nausea and early fullness in the two or three days after a weekly shot or a dose step, loose stools that people tie to metformin more than to the shot, and fewer stomach complaints once a dose has been steady for a few weeks.
PepVault's side-effect log records what you felt by day, next to the doses you logged, so you and your prescriber can see whether the nausea follows the shot day. Log it in PepVault
Why do vomiting and dehydration matter more on both?
Because the two labels meet at the kidneys. The GLP-1 labels warn of acute kidney injury (a sudden drop in kidney function) after fluid loss, mostly in people whose nausea, vomiting or diarrhea dried them out, and ask for kidney checks in people with those side effects, above all during the start and dose steps13. Metformin leaves the body through the kidneys, and its rare but serious side effect, lactic acidosis (a build-up of lactic acid in the blood), is more likely when the kidneys slow down. Its medication guide names dehydration from fever, vomiting or diarrhea among the risks5. Neither label calls this an interaction; it is the same weak point seen from two sides. Our guide on GLP-1s and the kidneys has the GLP-1 side in full.
- Tell the prescriber of each drug that you take the other, and name any insulin or sulfonylurea too.
- Ask ahead what to do with metformin on a day you cannot keep food or fluids down; its label pauses metformin while food and fluids are restricted around surgery5.
- Keep sipping fluids through a stretch of nausea or diarrhea; the GLP-1 labels ask you to avoid losing fluids13.
- Before surgery, sedation or a scan with contrast dye, tell the team you take both: metformin may be paused around some contrast scans5, and the GLP-1 labels flag food left in the stomach under anesthesia1.
- Keep the kidney blood test (eGFR) the metformin label asks for at least once a year5.
When to get help Vomiting or diarrhea that keeps you from holding down fluids, or feeling very weak with unusual muscle pain, trouble breathing or unusual sleepiness, is a reason to call your prescriber right away; for those last signs metformin's guide says to stop metformin until you have5.
Should you take metformin and a GLP-1 together for weight loss?
That is your prescriber's call, and the evidence for it is thin. Wegovy and Zepbound are the ones approved for weight24. Metformin is a type 2 diabetes drug that took off about 2% of body weight on its own in the Diabetes Prevention Program; our berberine vs metformin vs a GLP-1 guide has those numbers. For weight alone, the only randomized test of adding metformin to a GLP-1 is the 44-woman liraglutide trial above13.
PepVault keeps your weigh-ins and HbA1c results in one place, so the change after a new drug is added shows as a trend, not a single morning. Track your weight in PepVault
Sources
- Ozempic (semaglutide) injection, prescribing information, sections 5.5, 5.6, 5.10, 7, 12.3 and 14.1. Novo Nordisk. DailyMed SPL version 20, Jun 2026. dailymed.nlm.nih.gov
- Wegovy (semaglutide) injection and tablets, prescribing information, sections 1, 6.1, 7, 12.3 and 14. Novo Nordisk. DailyMed SPL version 19, Jun 2026. dailymed.nlm.nih.gov
- Mounjaro (tirzepatide) injection, prescribing information, sections 2, 5, 6.1, 7, 12.3 and 14.3. Eli Lilly. DailyMed SPL version 40, Sep 2026. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) injection, prescribing information, sections 1, 5.7, 6.1, 7 and 14. Eli Lilly. DailyMed SPL version 40, Sep 2026. dailymed.nlm.nih.gov
- Metformin hydrochloride tablets, prescribing information and medication guide, sections 2.1, 5.1, 5.3, 6.1 and 7. PD-Rx Pharmaceuticals. DailyMed SPL version 20, Nov 2026. dailymed.nlm.nih.gov
- Rybelsus and Ozempic (semaglutide) tablets, prescribing information, section 12.3. Novo Nordisk. DailyMed SPL version 14, Aug 2026. dailymed.nlm.nih.gov
- Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021. PubMed 34170647
- Ahrén B et al. Once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both (SUSTAIN 2). Lancet Diabetes Endocrinol. 2017. PubMed 28385659
- Rodbard HW et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019. PubMed 31530666
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021. PubMed 33667417
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PubMed 37385275
- Capehorn M et al. Once-weekly semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background common OAD: a subgroup analysis from SUSTAIN 2-4 and 10. Diabetes Ther. 2020. PubMed 32193837
- Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study. Exp Ther Med. 2016. PubMed 27073422
- Chen H et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a randomized, controlled, open-label trial. Reprod Biol Endocrinol. 2025. PubMed 40713699
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.